A recent paper from the Center for Technology Innovation and Governance Studies at the Brookings Institution in Washington makes the argument that the conventional technology transfer (TT) model at U.S. research universities, with its emphasis on patenting and licensing inventions funded by federal research grants, has failed to stem the nation’s so-called “innovation deficit.” Read More
A team from the Chinese Shenzhen Hospital and the University of California at San Diego has developed a way to prevent the immune rejection of embryonic stem (ES) cells. Read More
HONG KONG – One of China’s largest chemicals producers is stepping into the biotech space via its acquisition of a hepatitis B vaccine maker. The deal comes at a sensitive time for the sector following the deaths of at least seven children blamed on those vaccines and ongoing probes into the quality of vaccine manufacturing. Read More
U.S. biopharmaceutical companies capped 2013 with the strongest quarter of the year, raising $835 million in 37 venture capital deals in the fourth quarter according to data compiled by BioWorld Snapshots. Read More
Neuralstem Inc.’s $19.65 million from a stock offering will help advance the lead compound NSI-566 in amyotrophic lateral sclerosis (ALS), which is “about halfway through” a Phase II trial, said CEO Richard Garr. Read More
A startling report in The New England Journal of Medicine shows U.S. industry investment in biomedical research and development falling off a cliff over the past five years – and reappearing in Asia. Read More
LONDON – A drug under development for asthma that was dumped by Astrazeneca plc in July 2005 has been revived as a potential treatment for kidney cancer. Read More
Danish allergy vaccine firm ALK-Abello A/S said it expects to add DKK50 million to DKK52 million (US$9.1 million to US$9.5 million) to its earnings and its revenues in the coming year, because of a revision to Germany’s drug pricing regime that took effect on Jan. 1. Read More
Regenerx Biopharmaceuticals Inc., of Rockville, Md., said it received orphan drug designation from the FDA for its Thymosin beta 4 (Tbeta4) candidate for treating neurotrophic keratopathy (NK), a serious degenerative disease of the corneal epithelium. Read More
